Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

The mouse as a model for neuropsychiatric drug development.

Howe JR 6th, Bear MF, Golshani P, Klann E, Lipton SA, Mucke L, Sahin M, Silva AJ.

Curr Biol. 2018 Sep 10;28(17):R909-R914. doi: 10.1016/j.cub.2018.07.046.

PMID:
30205056
2.

Turning up translation in fragile X syndrome.

Aryal S, Klann E.

Science. 2018 Aug 17;361(6403):648-649. doi: 10.1126/science.aau6450. No abstract available.

PMID:
30115797
3.

Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.

Gross C, Banerjee A, Tiwari D, Longo F, White AR, Allen AG, Schroeder-Carter LM, Krzeski JC, Elsayed NA, Puckett R, Klann E, Rivero RA, Gourley SL, Bassell GJ.

Neuropsychopharmacology. 2018 Jul 13. doi: 10.1038/s41386-018-0150-5. [Epub ahead of print]

PMID:
30061744
4.
5.

Extinction of auditory threat memory triggers activation of p70 S6 kinase 1 in the basolateral nucleus of the amygdala.

Huynh TN, Santini E, Mojica E, Fink AE, Hall BS, Fetcho RN, Grosenick L, Deisseroth K, LeDoux JE, Liston C, Klann E.

Mol Psychiatry. 2018 Jun;23(6):1393. doi: 10.1038/mp.2018.8. No abstract available.

PMID:
29964271
6.

Parental Concerns About Students' Transition Into College: Substance Use and Sexual Assault.

Vaughan EL, Limas EF, McKean Blackwell N, Klann EM, Robbins MJ.

J Interpers Violence. 2017 Sep 1:886260517731787. doi: 10.1177/0886260517731787. [Epub ahead of print]

PMID:
29294925
7.

Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice.

Santini E, Huynh TN, Longo F, Koo SY, Mojica E, D'Andrea L, Bagni C, Klann E.

Sci Signal. 2017 Nov 7;10(504). pii: eaan0665. doi: 10.1126/scisignal.aan0665.

8.

Activation of a novel p70 S6 kinase 1-dependent intracellular cascade in the basolateral nucleus of the amygdala is required for the acquisition of extinction memory.

Huynh TN, Santini E, Mojica E, Fink AE, Hall BS, Fetcho RN, Grosenick L, Deisseroth K, LeDoux JE, Liston C, Klann E.

Mol Psychiatry. 2018 Jun;23(6):1394-1401. doi: 10.1038/mp.2017.99. Epub 2017 May 2.

9.

Accumulation of Polyribosomes in Dendritic Spine Heads, But Not Bases and Necks, during Memory Consolidation Depends on Cap-Dependent Translation Initiation.

Ostroff LE, Botsford B, Gindina S, Cowansage KK, LeDoux JE, Klann E, Hoeffer C.

J Neurosci. 2017 Feb 15;37(7):1862-1872. doi: 10.1523/JNEUROSCI.3301-16.2017. Epub 2017 Jan 13.

10.

Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer's Disease.

Beckelman BC, Day S, Zhou X, Donohue M, Gouras GK, Klann E, Keene CD, Ma T.

J Alzheimers Dis. 2016 Sep 6;54(2):669-78. doi: 10.3233/JAD-160036.

11.

Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.

Sahin M, Henske EP, Manning BD, Ess KC, Bissler JJ, Klann E, Kwiatkowski DJ, Roberds SL, Silva AJ, Hillaire-Clarke CS, Young LR, Zervas M, Mamounas LA; Tuberous Sclerosis Complex Working Group to Update the Research Plan.

Pediatr Neurol. 2016 Jul;60:1-12. doi: 10.1016/j.pediatrneurol.2016.03.015. Epub 2016 Apr 2.

12.

Deconstructing brain-derived neurotrophic factor actions in adult brain circuits to bridge an existing informational gap in neuro-cell biology.

Bowling H, Bhattacharya A, Klann E, Chao MV.

Neural Regen Res. 2016 Mar;11(3):363-7. doi: 10.4103/1673-5374.179031. Review.

13.

Repression of the eIF2α kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease.

Yang W, Zhou X, Zimmermann HR, Cavener DR, Klann E, Ma T.

Neurobiol Aging. 2016 May;41:19-24. doi: 10.1016/j.neurobiolaging.2016.02.005. Epub 2016 Feb 13.

14.

Genetically Dissecting Cortical Neurons Involved in Epilepsy in Angelman Syndrome.

Santini E, Klann E.

Neuron. 2016 Apr 6;90(1):1-3. doi: 10.1016/j.neuron.2016.03.023.

15.

Alzheimer's disease: Lost memories found.

Shrestha P, Klann E.

Nature. 2016 Mar 24;531(7595):450-1. doi: 10.1038/nature17312. Epub 2016 Mar 16. No abstract available.

PMID:
26982731
16.

Calmodulin activity regulates group I metabotropic glutamate receptor-mediated signal transduction and synaptic depression.

Sethna F, Zhang M, Kaphzan H, Klann E, Autio D, Cox CL, Wang H.

J Neurosci Res. 2016 May;94(5):401-8. doi: 10.1002/jnr.23719. Epub 2016 Feb 11.

17.

Cc2d1a Loss of Function Disrupts Functional and Morphological Development in Forebrain Neurons Leading to Cognitive and Social Deficits.

Oaks AW, Zamarbide M, Tambunan DE, Santini E, Di Costanzo S, Pond HL, Johnson MW, Lin J, Gonzalez DM, Boehler JF, Wu GK, Klann E, Walsh CA, Manzini MC.

Cereb Cortex. 2017 Feb 1;27(2):1670-1685. doi: 10.1093/cercor/bhw009.

PMID:
26826102
18.

Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.

Bhattacharya A, Mamcarz M, Mullins C, Choudhury A, Boyle RG, Smith DG, Walker DW, Klann E.

Neuropsychopharmacology. 2016 Jul;41(8):1991-2000. doi: 10.1038/npp.2015.369. Epub 2015 Dec 28.

19.

Mitochondrial Superoxide Contributes to Hippocampal Synaptic Dysfunction and Memory Deficits in Angelman Syndrome Model Mice.

Santini E, Turner KL, Ramaraj AB, Murphy MP, Klann E, Kaphzan H.

J Neurosci. 2015 Dec 9;35(49):16213-20. doi: 10.1523/JNEUROSCI.2246-15.2015.

20.

RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease.

Wong H, Levenga J, Cain P, Rothermel B, Klann E, Hoeffer C.

Acta Neuropathol. 2015 Dec;130(6):829-43. doi: 10.1007/s00401-015-1499-8. Epub 2015 Oct 24.

21.

Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism.

Huber KM, Klann E, Costa-Mattioli M, Zukin RS.

J Neurosci. 2015 Oct 14;35(41):13836-42. doi: 10.1523/JNEUROSCI.2656-15.2015. Review.

22.

Dysregulation and restoration of translational homeostasis in fragile X syndrome.

Richter JD, Bassell GJ, Klann E.

Nat Rev Neurosci. 2015 Oct;16(10):595-605. doi: 10.1038/nrn4001. Epub 2015 Sep 9. Review.

23.

eIF4E/Fmr1 double mutant mice display cognitive impairment in addition to ASD-like behaviors.

Huynh TN, Shah M, Koo SY, Faraud KS, Santini E, Klann E.

Neurobiol Dis. 2015 Nov;83:67-74. doi: 10.1016/j.nbd.2015.08.016. Epub 2015 Aug 22.

24.

BONLAC: A combinatorial proteomic technique to measure stimulus-induced translational profiles in brain slices.

Bowling H, Bhattacharya A, Zhang G, Lebowitz JZ, Alam D, Smith PT, Kirshenbaum K, Neubert TA, Vogel C, Chao MV, Klann E.

Neuropharmacology. 2016 Jan;100:76-89. doi: 10.1016/j.neuropharm.2015.07.017. Epub 2015 Jul 21.

25.

Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome.

Gross C, Chang CW, Kelly SM, Bhattacharya A, McBride SM, Danielson SW, Jiang MQ, Chan CB, Ye K, Gibson JR, Klann E, Jongens TA, Moberg KH, Huber KM, Bassell GJ.

Cell Rep. 2015 May 5;11(5):727-36. doi: 10.1016/j.celrep.2015.03.060. Epub 2015 Apr 23.

26.

How ketamine helps to overcome depression.

Huynh TN, Klann E.

Elife. 2014 Dec 12;3:e05418. doi: 10.7554/eLife.05418.

27.

Reciprocal signaling between translational control pathways and synaptic proteins in autism spectrum disorders.

Santini E, Klann E.

Sci Signal. 2014 Oct 28;7(349):re10. doi: 10.1126/scisignal.2005832. Review.

28.

In-depth quantitative proteomic analysis of de novo protein synthesis induced by brain-derived neurotrophic factor.

Zhang G, Bowling H, Hom N, Kirshenbaum K, Klann E, Chao MV, Neubert TA.

J Proteome Res. 2014 Dec 5;13(12):5707-14. doi: 10.1021/pr5006982. Epub 2014 Oct 13.

29.

Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.

Kumari D, Bhattacharya A, Nadel J, Moulton K, Zeak NM, Glicksman A, Dobkin C, Brick DJ, Schwartz PH, Smith CB, Klann E, Usdin K.

Hum Mutat. 2014 Dec;35(12):1485-94. doi: 10.1002/humu.22699.

30.

Shaping dendritic spines in autism spectrum disorder: mTORC1-dependent macroautophagy.

Bowling H, Klann E.

Neuron. 2014 Sep 3;83(5):994-6. doi: 10.1016/j.neuron.2014.08.021.

31.

Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

Ma T, Chen Y, Vingtdeux V, Zhao H, Viollet B, Marambaud P, Klann E.

J Neurosci. 2014 Sep 3;34(36):12230-8. doi: 10.1523/JNEUROSCI.1694-14.2014.

32.

Effects of acute sleep deprivation on motor and reversal learning in mice.

Varga AW, Kang M, Ramesh PV, Klann E.

Neurobiol Learn Mem. 2014 Oct;114:217-22. doi: 10.1016/j.nlm.2014.07.001. Epub 2014 Jul 18.

33.

PERK: a novel therapeutic target for neurodegenerative diseases?

Ma T, Klann E.

Alzheimers Res Ther. 2014 May 29;6(3):30. doi: 10.1186/alzrt260. eCollection 2014.

34.

Requirement of Mammalian target of rapamycin complex 1 downstream effectors in cued fear memory reconsolidation and its persistence.

Huynh TN, Santini E, Klann E.

J Neurosci. 2014 Jul 2;34(27):9034-9. doi: 10.1523/JNEUROSCI.0878-14.2014.

35.

The eIF2α kinase PERK limits the expression of hippocampal metabotropic glutamate receptor-dependent long-term depression.

Trinh MA, Ma T, Kaphzan H, Bhattacharya A, Antion MD, Cavener DR, Hoeffer CA, Klann E.

Learn Mem. 2014 Apr 16;21(5):298-304. doi: 10.1101/lm.032219.113.

36.

Prohibitin viral gene transfer protects hippocampal CA1 neurons from ischemia and ameliorates postischemic hippocampal dysfunction.

Kurinami H, Shimamura M, Ma T, Qian L, Koizumi K, Park L, Klann E, Manfredi G, Iadecola C, Zhou P.

Stroke. 2014 Apr;45(4):1131-8. doi: 10.1161/STROKEAHA.113.003577. Epub 2014 Mar 11.

37.

Mechanisms of translation control underlying long-lasting synaptic plasticity and the consolidation of long-term memory.

Santini E, Huynh TN, Klann E.

Prog Mol Biol Transl Sci. 2014;122:131-67. doi: 10.1016/B978-0-12-420170-5.00005-2. Review.

38.

Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity.

Bowling H, Zhang G, Bhattacharya A, Pérez-Cuesta LM, Deinhardt K, Hoeffer CA, Neubert TA, Gan WB, Klann E, Chao MV.

Sci Signal. 2014 Jan 14;7(308):ra4. doi: 10.1126/scisignal.2004331.

39.

(Li+)ghting the way for a treatment for cognitive impairments in fragile X syndrome.

Bhattacharya A, Klann E.

Biol Psychiatry. 2014 Feb 1;75(3):175-6. doi: 10.1016/j.biopsych.2013.11.017. No abstract available.

PMID:
24370350
40.

Regulator of calcineurin 1 modulates expression of innate anxiety and anxiogenic responses to selective serotonin reuptake inhibitor treatment.

Hoeffer CA, Wong H, Cain P, Levenga J, Cowansage KK, Choi Y, Davy C, Majmundar N, McMillan DR, Rothermel BA, Klann E.

J Neurosci. 2013 Oct 23;33(43):16930-44. doi: 10.1523/JNEUROSCI.3513-12.2013.

41.

Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology.

Udagawa T, Farny NG, Jakovcevski M, Kaphzan H, Alarcon JM, Anilkumar S, Ivshina M, Hurt JA, Nagaoka K, Nalavadi VC, Lorenz LJ, Bassell GJ, Akbarian S, Chattarji S, Klann E, Richter JD.

Nat Med. 2013 Nov;19(11):1473-7. doi: 10.1038/nm.3353. Epub 2013 Oct 20.

42.

Coordinate regulation of mature dopaminergic axon morphology by macroautophagy and the PTEN signaling pathway.

Inoue K, Rispoli J, Yang L, Macleod D, Beal MF, Klann E, Abeliovich A.

PLoS Genet. 2013;9(10):e1003845. doi: 10.1371/journal.pgen.1003845. Epub 2013 Oct 3.

43.

Basal variability in CREB phosphorylation predicts trait-like differences in amygdala-dependent memory.

Cowansage KK, Bush DE, Josselyn SA, Klann E, Ledoux JE.

Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16645-50. doi: 10.1073/pnas.1304665110. Epub 2013 Sep 23.

44.

CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation.

De Rubeis S, Pasciuto E, Li KW, Fernández E, Di Marino D, Buzzi A, Ostroff LE, Klann E, Zwartkruis FJ, Komiyama NH, Grant SG, Poujol C, Choquet D, Achsel T, Posthuma D, Smit AB, Bagni C.

Neuron. 2013 Sep 18;79(6):1169-82. doi: 10.1016/j.neuron.2013.06.039.

45.

Molecular and cellular cognition: Neurobiology of Learning and Memory Special Issue 2013.

Abel T, Klann E.

Neurobiol Learn Mem. 2013 Oct;105:1-2. doi: 10.1016/j.nlm.2013.08.005. No abstract available.

PMID:
24011364
46.

Suppression of eIF2α kinases alleviates Alzheimer's disease-related plasticity and memory deficits.

Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, Cavener DR, Klann E.

Nat Neurosci. 2013 Sep;16(9):1299-305. doi: 10.1038/nn.3486. Epub 2013 Aug 11.

47.

Genetic reduction of the α1 subunit of Na/K-ATPase corrects multiple hippocampal phenotypes in Angelman syndrome.

Kaphzan H, Buffington SA, Ramaraj AB, Lingrel JB, Rasband MN, Santini E, Klann E.

Cell Rep. 2013 Aug 15;4(3):405-12. doi: 10.1016/j.celrep.2013.07.005. Epub 2013 Aug 1.

48.

Translational control by eIF2α kinases in long-lasting synaptic plasticity and long-term memory.

Trinh MA, Klann E.

Neurobiol Learn Mem. 2013 Oct;105:93-9. doi: 10.1016/j.nlm.2013.04.013. Epub 2013 May 22. Review.

49.

The translation of translational control by FMRP: therapeutic targets for FXS.

Darnell JC, Klann E.

Nat Neurosci. 2013 Nov;16(11):1530-6. doi: 10.1038/nn.3379. Epub 2013 Apr 14. Review.

50.

Exaggerated translation causes synaptic and behavioural aberrations associated with autism.

Santini E, Huynh TN, MacAskill AF, Carter AG, Pierre P, Ruggero D, Kaphzan H, Klann E.

Nature. 2013 Jan 17;493(7432):411-5. doi: 10.1038/nature11782. Epub 2012 Dec 23.

Supplemental Content

Support Center